oral glp 1 agonists FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest Oral Non Peptide GLP 1

Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort

Systemic use (injections) will not yield the free copper levels needed to inhibit 5AR anywhere in the body

This point was recently confirmed in a large study by Xu and collaborators (Xu et al., 2020)

- *Domperidone*: A prokinetic agent that enhances gastrointestinal motility, helping to: - *Relieve Nausea and Vomiting*: Associated with various conditions, including gastroparesis or medication side effects

Research suggests it may also activate CD36 receptors (a scavenger receptor involved in fatty acid uptake), which may explain its unique cardiovascular effects not seen with other GHRPs (Bhatt et al., 2002)